Polyphenols in the prevention and treatment of non-alcoholic fatty liver disease: An update of preclinical and clinical studies

Basit Öğe Kaydı
dc.authoridhttps://orcid.org/0000-0002-7073-2907en_US
dc.authoridhttps://orcid.org/0000-0001-7982-6988en_US
dc.contributor.authorBayram, Hatice Merve
dc.contributor.authorMajoo, Fuzail Mohammed
dc.contributor.authorÖztürkcan, S. Arda
dc.date.accessioned2023-08-02T20:46:01Z
dc.date.available2023-08-02T20:46:01Z
dc.date.issued2021en_US
dc.departmentSağlık Bilimleri Fakültesien_US
dc.description.abstractBackground & aims: The prevention and treatment of non-alcoholic fatty liver disease (NAFLD) has become one of the most urgent problems to be solved. To date, only a lifestyle modification related to diet and physical activity is considered for these patients. Polyphenols are a group of plant natural products that when regularly consumed has been related to a reduction in the risk of several metabolic disorders associated with NAFLD. In this study, we aimed to present an overview of the relationship between polyphenols and NAFLD with current approaches. Methods: We performed a comprehensive literature search for articles on polyphenols and NAFLD published in English between January 2018 to August 2020. Keywords included in this review: “Phenolic” OR “Polyphenol” AND “Non-Alcoholic Fatty Liver Disease”. The editorials, communications and conference abstracts were excluded. Results: Different polyphenols decreased the pro-inflammatory cytokines in both serum and liver that contribute to a decrease in fatty liver dysfunction. Additionally, polyphenols may improve the regulation of adipokines and prevent hepatic steatosis. According to human clinical studies, polyphenols are promising for NAFLD patients and associated diseases that lead to NAFLD. Conclusion: Preclinical and clinical studies suggest that various polyphenols could prevent steatosis and its progression to non-alcoholic steatohepatitis, as well as ameliorate NAFLD. However, more clinical studies are needed to confirm this hypothesis.en_US
dc.identifier.doi10.1016/j.clnesp.2021.06.026en_US
dc.identifier.endpage14en_US
dc.identifier.issn2405-4577
dc.identifier.pmid34330452en_US
dc.identifier.scopus2-s2.0-85110380673en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://hdl.handle.net/11363/5157
dc.identifier.urihttps://doi.org/
dc.identifier.volume44en_US
dc.identifier.wosWOS:000678558000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBayram, Hatice Merve
dc.institutionauthorMajoo, Fuzail Mohammed
dc.institutionauthorÖztürkcan, S. Arda
dc.language.isoenen_US
dc.publisherELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDSen_US
dc.relation.ispartofClinical Nutrition ESPENen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectPolyphenolsen_US
dc.subjectNatural productsen_US
dc.subjectNon-alcoholic fatty liver diseaseen_US
dc.subjectPreclinical studiesen_US
dc.subjectHuman clinical studiesen_US
dc.titlePolyphenols in the prevention and treatment of non-alcoholic fatty liver disease: An update of preclinical and clinical studiesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1-s2.0-S2405457721002370-main.pdf
Boyut:
886.89 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale / Article
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
license.txt
Boyut:
1.56 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Web of Science ve Scopus Atıf Dizinlerindeki Yayınlar
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu